Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30784204,limits of detection (LODs),"The limits of detection (LODs) were 0.1 ng/mL, 0.2 ng/mL, and 0.05 ng/mL in serum, urine, and oral fluid.",Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784204/),[ng] / [ml],0.1,208177,DB00830,Phenmetrazine
,30784204,limits of detection (LODs),"The limits of detection (LODs) were 0.1 ng/mL, 0.2 ng/mL, and 0.05 ng/mL in serum, urine, and oral fluid.",Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784204/),[ng] / [ml],0.2,208178,DB00830,Phenmetrazine
,30784204,limits of detection (LODs),"The limits of detection (LODs) were 0.1 ng/mL, 0.2 ng/mL, and 0.05 ng/mL in serum, urine, and oral fluid.",Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784204/),[ng] / [ml],0.05,208179,DB00830,Phenmetrazine
,30784204,highest serum concentration (cmax ),The highest serum concentration (cmax ) of 210 ng/mL was reached 2.5 hours (tmax ) after ingestion.,Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784204/),[ng] / [ml],210,208180,DB00830,Phenmetrazine
,30784204,tmax,The highest serum concentration (cmax ) of 210 ng/mL was reached 2.5 hours (tmax ) after ingestion.,Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784204/),h,2.5,208181,DB00830,Phenmetrazine
